Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: IDegLira

First Posted Date: 2023-11-02

Last Posted Date: 2024-09-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 266

Registration Number: NCT06113341

Locations: 🇮🇹
Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, Italy
🇮🇹
Ospedale San Francesco d'Assisi, Oliveto Citra, Italy
🇮🇹
Presidio Ospedaliero Santa Barbara, Iglesias, Italy

and more 15 locations

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Conditions: Growth Hormone Deficiency in Children

Interventions: Drug: Somapacitan

First Posted Date: 2023-10-31

Last Posted Date: 2024-08-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 200

Registration Number: NCT06109935

Locations: 🇯🇵
Asahikawa Medical Univ. Hospital, Pediatrics, Asahikawa, Hokkaido, Japan
🇯🇵
Beppu Medical Center, Beppu-shi, Oita-ken, Japan
🇯🇵
Fukuoka University Hospital, Fukuoka-shi, Fukuoka-ken, Japan

and more 44 locations

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Semaglutide

First Posted Date: 2023-10-24

Last Posted Date: 2024-07-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 121

Registration Number: NCT06097390

Locations: 🇨🇦
Altasciences Clinical Company, Inc, Montreal, Quebec, Canada

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Phase 3

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Metformin
Drug: Empagliflozin

First Posted Date: 2023-10-16

Last Posted Date: 2024-02-26

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT06083675

Locations: 🇹🇭
Songklanagarind Hospital, Songkla, Thailand
🇬🇷
General Hospital of Thessaloniki "G.Papanikolaou", Thessaloniki, Greece
🇵🇱
ETG Siedlce, Siedlce, Masovian, Poland

and more 97 locations

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: NNC0113-6856
Drug: Placebo

First Posted Date: 2023-10-06

Last Posted Date: 2024-01-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 170

Registration Number: NCT06069895

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Cagrilintide
Drug: Placebo cagrilintide
Drug: Placebo semaglutide
Drug: Semaglutide

First Posted Date: 2023-10-04

Last Posted Date: 2024-11-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2700

Registration Number: NCT06065540

Locations: 🇷🇸
CHC Zvezdara, Clinical department for endocrinology, Belgrade, Serbia
🇪🇸
Hospital General de Segovia, Segovia, Spain
🇹🇷
Tekirdag Namık Kemal UTF, Tekirdag, Turkey

and more 343 locations

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Phase 2

Recruiting

Conditions: Obesity
Overweight

Interventions: Drug: NNC0487-0111
Drug: Placebo (NNC0487-0111)

First Posted Date: 2023-10-03

Last Posted Date: 2024-06-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 120

Registration Number: NCT06064006

Locations: 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
🇺🇸
Novo Nordisk INvestigational Site, San Antonio, Texas, United States

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Placebo (NNC0487-0111)
Drug: NNC0487-0111

First Posted Date: 2023-09-22

Last Posted Date: 2024-03-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT06049329

Locations: 🇯🇵
Hakata Clinic, Fukuoka, Japan

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

Phase 3

Active, not recruiting

Conditions: Overweight
Obesity

Interventions: Drug: Placebo
Drug: Semaglutide

First Posted Date: 2023-09-18

Last Posted Date: 2024-12-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 162

Registration Number: NCT06041217

Locations: 🇨🇳
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan
🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳
Fujian Medical University Union Hospital-Endocrinology, Fuzhou, Fujian, China

and more 17 locations

A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Semaglutide

First Posted Date: 2023-08-18

Last Posted Date: 2024-08-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 121

Registration Number: NCT05996874

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy